AUTL250117P5000
- 0.00
- 0.000.00%
Autolus Therapeutics Newsroom
Autolus Therapeutics Analyst Ratings
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Redburn Atlantic Initiates Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $13
Autolus Therapeutics Upgraded to Buy From Neutral at Redburn Atlantic
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $8 to $13
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $8 to $10
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics Analyst Ratings
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $9
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics (AUTL) Gets a Buy From Truist Financial
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $11